Aileron Announces Poster Presentations at Two Scientific Conferences in November
Poster presentation at the
Poster presentation at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Poster Title: “The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models”
Location: Walter E. Washington Convention Center, Hall E
EORTC/NCI/AACR Symposium Details
Poster Title: “Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies”
Session Name: Molecular Targeted Agents - PART II
Location: The Convention Centre Dublin, Exhibition Hall
ALRN-6924 is a first-in-class product candidate designed to reactivate wild-type p53 tumor suppression by disrupting the interactions between p53 and its two primary suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of acute myeloid leukemia (AML), advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL). For information about its clinical trials, please visit www.clinicaltrials.gov.
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform capable of engineering cell-penetrating alpha-helical peptides to address previously undruggable intracellular targets in oncology and other therapeutic areas. Our alpha-helical peptides are engineered to create potentially safe and effective therapies for patients. We leverage our internal expertise in peptide chemistry to design and develop specialized peptides with unique drug-like properties such as ALRN-6924. Our current focus is to improve the standard of care for patients with hematological and solid tumors. For more information, visit www.aileronrx.com and for more information about our clinical trials, please visit www.clinicaltrials.gov.
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the
LifeSci Advisors, LLC.
Source: Aileron Therapeutics, Inc.